Amy E Krambeck
· Professor, UrologyVerifiedNorthwestern University · Urology
Active 2002–2025
About
Amy E Krambeck is the Chief of Endourology and Stone Disease in the Department of Urology at Northwestern University Feinberg School of Medicine. She holds the title of Edmund Andrews Professor of Urology and is a professor within the Urology department. Her professional focus includes endourology and stone disease, contributing to the academic and clinical excellence of the department. Her role involves leadership in these specialized areas of urology, supporting both research and patient care.
Research topics
- Medicine
- Surgery
- Internal medicine
- Urology
- Mineralogy
- Geology
- Paleontology
- Chemistry
- Radiology
- Geochemistry
Selected publications
Effect of prior HoLEP procedure on multiparametric MRI accuracy in detection of prostate cancer
BJUI Compass · 2025-11-01
articleOpen accessAbstract Objectives The objective of this study is to evaluate whether prior Holmium laser enucleation of the prostate (HoLEP) affects the diagnostic accuracy of multiparametric prostate MRI (mpMRI) with PI‐RADS scoring for detecting clinically significant prostate cancer (csPCa) on biopsy. Patients and Methods We queried the Northwestern Electronic Data Warehouse for all patients who underwent mpMRI followed by prostate biopsy. Demographic information, mpMRI data including PI‐RADS score and biopsy data including Gleason grade (GG) were collected. Patients were stratified based on prior HoLEP and highest PI‐RADS score of index lesion on MRI. The outcome of interest was detection of csPCa (GG ≥ 2) on biopsy. Logistic regression was performed to assess the impact of prior HoLEP on the detection of csPCa at time of biopsy. Results A total of 8937 patients met inclusion criteria, of which 97 patients (1.1%) had prior HoLEP. HoLEP specimen revealed benign pathology in 38 patients (39.2%), GG1 in 32 patients (33.0%), GG2 in 25 patients (25.8%) and GG3 in 2 patients (2.1%). Average time from HoLEP to mpMRI was 11.5 months. The post‐HoLEP group had lower prostate volumes (median 25.0 vs. 47.0 cc; p < 0.001) and PSA density (median 0.06 vs. 0.12 ng/ml 2 ; p < 0.001). Rates of csPCa detection based on highest PI‐RADS score were comparable between control and HoLEP groups. Prior HoLEP did not significantly affect the detection of csPCa on multivariable analysis adjusting for age, race, PI‐RADS, family history of PCa, and PSA density (OR = 0.97; 95% CI: 0.60–1.57). Conclusion PI‐RADS remains a reliable predictor of csPCa after HoLEP despite anatomic alterations. mpMRI should continue to guide biopsy and risk stratification in this population, though larger validation is warranted.
The Journal of Urology · 2025-04-08
articleSenior authorThe Journal of Urology · 2025-04-08
articleSenior authorWaiting for HoLEP—outcomes when complications arise in the preoperative period
World Journal of Urology · 2025-08-18
articleSenior authorLaser Enucleation Therapy for Benign Prostatic Hyperplasia
Urologic Clinics of North America · 2025-08-18 · 1 citations
reviewSenior authorTherapeutic Advances in Urology · 2025-01-01 · 1 citations
articleOpen accessSenior authorBackground: Prostatitis can be challenging to treat. In refractory cases, prostatitis can be treated surgically with transurethral resection. Objectives: To examine the safety and efficacy of holmium laser enucleation of the prostate (HoLEP) as treatment in patients with prostatitis. Design and methods: Patients who underwent HoLEP at a single center between January 2021 and August 2023 were retrospectively reviewed. Preoperative, intraoperative, and postoperative parameters were collected and analyzed. Patients with an ICD-10 diagnosis of prostatitis were identified and contacted postoperatively to evaluate for recurrent symptoms. Statistical significance was defined as p < 0.05. Results: We identified 918 patients, of whom 26 (2.8%) had a diagnosis of prostatitis. There were no differences in baseline characteristics between patients with and without prostatitis. Patients with prostatitis were less likely to have a history of a neurologic disorder ( p = 0.035), less likely to be catheter-dependent ( p = 0.005), and less likely to have a preoperative positive urine culture ( p = 0.040). There were no significant differences in intraoperative and postoperative parameters between the two groups. There were 23/26 (88.5%) patients with follow-up. There were no episodes of recurrent prostatitis and one episode of UTI after surgery, with a mean follow-up of 19.39 months (range: 7.45–30.19, SD: 7.38). Conclusion: Prostatitis patients undergoing HoLEP had comparable safety and efficacy profiles to those who did not have prostatitis. On follow-up, 100% of patients with prostatitis did not experience recurrent prostatitis, suggesting that HoLEP may have a role in the management of prostatitis in the presence of benign prostatic enlargement.
The Journal of Urology · 2025-04-08
articleThe Journal of Urology · 2025-04-08
articleUrolithiasis · 2025-07-23 · 1 citations
articleThe Journal of Urology · 2025-04-08
articleSenior author
Frequent coauthors
- 311 shared
James E. Lingeman
Indiana University School of Medicine
- 223 shared
Tim Large
- 183 shared
Marcelino Rivera
- 134 shared
Charles U. Nottingham
- 94 shared
Deepak Agarwal
University of Minnesota
- 80 shared
Joshua Heiman
Indiana University – Purdue University Indianapolis
- 78 shared
Mark A. Assmus
- 72 shared
John C. Lieske
Mayo Clinic
Education
M.D.
Northwestern University Feinberg School of Medicine
B.S.
University of Illinois at Urbana-Champaign
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Amy E Krambeck
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup